SMAD2 and chronic kidney disease: Studies have indicated that TGF-β1 can activate Smad2 and Smad3, which then activate myofibroblasts, leading to excessive production of extracellular matrix (ECM) and inhibition of ECM degradation, thereby inducing renal fibrosis and ultimately chronic renal failure (32).